Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.

Korinna Karampampa Wenjie Zhang Meena Venkatachalam Francois-Emery Cotté Devender Dhanda

Published in: Journal of medical economics (2023)

Ide-cel was associated with significant survival improvements in terms of both LYs and QALYs in patients with progressive triple-class-exposed RRMM. The ICER for ide-cel was similar to that of other approved and reimbursed RRMM therapies.

Keyphrases

multiple myeloma
end stage renal disease
healthcare
ejection fraction
newly diagnosed
multiple sclerosis
acute lymphoblastic leukemia
palliative care
acute myeloid leukemia
peritoneal dialysis
prognostic factors
diffuse large b cell lymphoma
chronic pain
patient reported